Synektik Sa · GPW:SNT
Synektik Sa — H1 FY2024 Earnings Presentation
21 slides from Synektik Sa's earnings presentation, June 2025
Slide 1: Investor Presentation H1 FY 2024: Financial results
SYNEKTIK SA Investor Presentation H1 FY 2024: Financial results June 2025 H1 FY 2024 Financial results | Investor presentation 1
Slide 2: Synektik in snapshot
Synektik in snapshot WIG, mWIG40, Indexes WIGTECH, WIG-Poland ISIN PLSNKTK0001 328m 81m Number of shares 8 529 129 PLN PLN Capitalisation(1) PLN 1.85bn REVENUE FROM SALES, EBITDA FROM CONTINUING Enterprise value(2) PLN 1.83bn H1 FY2024 OPERATIONS H1 FY2024 P/E(3) 18.4 EV/EBITDA(4) 12,5 Company profi
Slide 3: Highlights of H1 FY2024
Highlights of H1 FY2024 Sales of equipment and IT solutions – growing recurring revenues ▪ PLN 304.3 million in revenue (excluding intra-group transactions) in H1 FY 2024, including PLN 145.5 million in recurring revenue (64% YoY growth) ▪ Expansion into the Baltic countries; establishment of Synekt
Slide 4: Financial performance in Q2 FY2024
Financial performance in Q2 FY2024 Consolidated revenue (PLN million) ▪ 51% increase in total revenue from sales of equipment, IT solutions and Q2 FY2024 124.7 services (excluding intra-group transactions) +42% Q2 FY2023 87.7 ▪ 9% decrease in revenue of the radiopharmaceuticals segment, excluding in
Slide 5: Financial performance in H1 FY2024
Financial performance in H1 FY2024 Consolidated revenue (PLN million) ▪ PLN 304.3 million in revenue from the sale of equipment, IT solutions and services (excluding intra-group transactions), compared to PLN 336.5 million H1 FY2024 327.8 in revenue in H1 FY 2023 -9% H1 FY2023 359.0 ▪ 5% increase in
Slide 6: Group's adjusted EBITDA in FY 2021-2024
Group’s adjusted* EBITDA in FY 2021-2024 Adjusted* EBITDA EBITDA growth driven by: (PLNm) 52.7 50.5 ▪ Growing scale of recurring sales in both segments, characterized by attractive 29.8 30.4 31.7 31.7 33.8 margins 24.9 24.9 13.3 ▪ Increase in sales of equipment used in 10.9 5.5 6.2 7.1 therapy Q1 20
Slide 7: Group's recurring sales in FY 2021-2024
Group’s recurring sales in FY 2021-2024 Recurring revenue for past 4 quarters Dynamic growth of recurring revenue (PLNm) 33.2 Drivers: 31.9 ▪ Dynamically increasing demand for consumable parts and accessories for therapy equipment sold 31.5 by the Synektik Group Revenue from sales of radiopharmaceut
Slide 8: Selected financial data
Selected financial data PLN 000s Q2 FY 2024 Q2 FY 2023 H1 FY 2024 H1 FY 2023 Sales revenue 124 694 87 703 327 822 358 999 ▪ Cash surplus over financial liabilities amounting to EBIT* 25 406 20 979 71 061 69 761 nearly PLN 21 million as of March 31, 2025 EBIT margin* 20.4% 23.9% 21.7% 19.4% EBITDA* 3
Slide 9: Medical equipment and IT solutions
SYNEKTIK SA Medical equipment and IT solutions H1 FY 2024 Financial results | Investor presentation 9
Slide 10: Medical equipment and IT solutions: Key information
Medical equipment and IT solutions Key information Synektik is a leading provider of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Core areas: ▪ Sale of medical equipment from several leading manufacturers, used in radiology, therapy and nuclear medicine ▪
Slide 11: Medical equipment and IT solutions: Financial results
Medical equipment and IT solutions Financial results (PLN million) Growing business profitabiity 336.5 304.3 ▪ PLN 304.3 million in revenue in H1 FY 2024, compared to PLN 336.5 million the year before ▪ PLN 82.8 million EBITDA in H1 FY 2024; increase in EBITDA segment profitability by 76.6 82.8 4.5
Slide 12: Medical equipment and IT solutions: Promising prospects
Medical equipment and IT solutions Promising prospects for the coming quarters Sales of medical equipment, orders for implementation and active offers (in PLN million) ▪ Secured orders worth PLN 147 million in H1 FY 2024 247.5 ▪ The value of active offers as of the end of March 2025 is PLN 222.4 mil
Slide 13: Commercialization of da Vinci system
Medical equipment and IT solutions Commercialization of da Vinci system Da Vinci assisted surgical procedures in Poland, Czech Republic and 96 9000 Slovakia (number) 8000 ▪ Approximately 4.8 thousand surgeries with the assistance of da Vinci in Q2 FY 2024 in Poland (up 77% y/y), 15.7 thousand in the
Slide 14: Da Vinci systems serviced by Synektik
Medical equipment and IT solutions Gdynia Da Vinci serviced by GK Synektik Słupsk Gdańsk Olsztyn 66 Białystok 100 Szczecin Bydgoszcz Toruń Wieliszew Biała Podlaska Grodzisk Da Vinci systems serviced da Vinci systems Gorzów Wlkp. Maz. by GK Synektik in Poland* Poznań Warszawa Siedlce Zielona Góra Les
Slide 15: Radiopharmaceuticals
SYNEKTIK SA Radiopharmaceuticals H1 FY 2024 Financial results | Investor presentation 15
Slide 16: Radiopharmaceuticals: Key information
Radiopharmaceuticals Key information ▪ Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland 50+ Number of 3 Production sites together employees with R&D Centre ▪ Major producer of special radiopharmaceuticals Location of cyclotrons for the production of radiopharmac
Slide 17: Radiopharmaceuticals: Financial results
Radiopharmaceuticals Financial results (million PLN ) 23.6 Growing revenues 22.5 ▪ 5% increase in sales (year-over-year) in H1 FY 2024, up to PLN 23.6 million 8.5 7.7 ▪ 9% increase in sales of basic markers, up to PLN 12.6 million ▪ 16% increase in sales of special markers, up to PLN 4.8 million H1
Slide 18: Cardiotracer
SYNEKTIK SA Cardiotracer H1 FY 2024 Financial results | Investor presentation 18
Slide 19: Spinning off the cardiotracer research project – key informations
Spinning off the cardiotracer research project – key informations ▪ Adoption, in March of the current year, of a strategic resolution by the Management Board of Synektik to initiate a process aimed at dividing the Group into two independent publicly listed entities: ▪ Syn2bio SA – to take over the c
Slide 20: Q&A SESSION
SYNEKTIK SA Q&A SESSION H1 FY 2024 Financial results | Investor presentation 20
Slide 21: Thank you!
Cezary Kozanecki Thank you! President of the Management Board, CEO ckozanecki@synektik.com.pl Dariusz Korecki Vice-President of the Management Board, CFO dkorecki@synektik.com.pl